Brain Neoplasms Clinical Trial
Official title:
Comparative Study Between Different Approaches to CPA -Petroclival Meningiomas
• Give an effective treatment for CPA-petroclival meningiomas and can detect the best
approach for these tumors.
. Improve the outcome of these patients and decease rate of recurrence.
There are several lesions arising in the petroclival region. The most frequent tumor is the
petroclival meningioma, followed by chondrosarcomas, chordomas, schwannomas of the cranial
nerves V and VII, and other malignant tumors [1, 2, 3, 4, 5].
Petroclival meningiomas are tumors of the skull base that present a formidable challenge to
surgical resection because of their deep location and relationship to vital neurovascular
structures. In the majority of the cases they are benign tumors, but may involve or
infiltrate the skull base bone, the dura mater, the brainstem, and all important
neurovascular structures of this region. The petroclival region comprises the anatomical
location of the body of the sphenoid bone, the anterior central portion of the occipital
bone, and is bordered on the lateral aspect by the petrous apex. The roof of this space is
formed by the petroclival ligaments and the tentorium. This space contains important
neurovascular structures that are frequently involved or displaced by the tumor in a variable
pattern. The basilar artery with its branches may be embedded or displaced by the meningioma.
The petrosal vein is often displaced posteriorly by the tumor. Cranial nerves III and IV are
usually displaced upwardly and the nerve VI is often surrounded by tumor. Petroclival
meningiomas have their origin medial to cranial nerves V, VII, VIII, IX, X, and XI, and reach
the tentorium . They frequently extend to the middle cranial fossa, cavernous sinus,
prepontine space, and down to the foramen magnum. These tumors frequently compress the
brainstem making total removal very difficult or impossible without neurologic deficits.
cerebellopontine angle (CPA) and low clivus meningiomas may reach these areas. These lesions
usually need different surgical approaches as transpetrosal approach ( anterior, modified and
combined ) and retrosigmoid approach
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02810899 -
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
|
Phase 4 | |
Withdrawn |
NCT00977795 -
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT00787982 -
Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00555984 -
Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors
|
N/A | |
Completed |
NCT00038441 -
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT03619694 -
Role of MR Spectroscopy in Brain Tumors
|
||
Withdrawn |
NCT01236586 -
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Unknown status |
NCT02775136 -
An Evaluation of a Non-invasive Brain Monitor
|
N/A | |
Completed |
NCT01244737 -
FLT-PET Imaging of Brain Tumors in Children
|
Phase 2 | |
Completed |
NCT00993057 -
Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia
|
Early Phase 1 | |
Terminated |
NCT00769093 -
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
|
Phase 1 | |
Completed |
NCT00392119 -
MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors
|
Phase 1 | |
Terminated |
NCT00038389 -
Study of Vioxx and Radiation Therapy for Brainstem Glioma
|
Phase 1 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Recruiting |
NCT05049148 -
Platelets Activation in Brain Neoplasms
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT04712721 -
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
|
Early Phase 1 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01954576 -
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
N/A | |
Recruiting |
NCT05538130 -
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
|
Phase 1 |